PMID- 23926306
OWN - NLM
STAT- MEDLINE
DCOM- 20131115
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 122
IP  - 12
DP  - 2013 Sep 19
TI  - Thalidomide corrects impaired mesenchymal stem cell function in inducing 
      tolerogenic DCs in patients with immune thrombocytopenia.
PG  - 2074-82
LID - 10.1182/blood-2013-03-491555 [doi]
AB  - Thalidomide (THD) is an immunomodulatory agent used to treat immune-mediated 
      diseases. Immune thrombocytopenia (ITP) is an autoimmune disorder in which 
      impaired mesenchymal stem cells (MSCs) are potentially involved. We demonstrated 
      that MSCs in ITP patients had reduced proliferative capacity and lost their 
      immunosuppressive function, which could be corrected with THD treatment. 
      According to the gene profile, the downregulation of caspase-8 and caspase-10, 
      and upregulation of oct3/4 and tgf-beta1, may be associated with THD modulation. 
      Dendritic cells (DCs) played an important role in mediating the inhibitory 
      activity of MSCs. To study the functional alteration of DCs elicited by MSCs, we 
      sorted DCs after incubation with MSCs and performed T-lymphocyte reaction assays. 
      The THD-modulated MSCs from ITP patients induced mature DCs to become tolerogenic 
      DCs, whereas unmodulated MSCs had no effect. The induction of tolerogenicity in 
      DCs by MSCs was dependent on the expression of TIEG1 in DCs. The study reveals 
      the inability of MSCs from ITP patients to induce tolerogenic ability in DCs. THD 
      could restore the regulatory effect of MSCs on DCs. These findings will help us 
      understand the pathogenesis of ITP, and with appropriate safeguards, THD may 
      benefit patients with ITP.
FAU - Ma, Ji
AU  - Ma J
AD  - Department of Hematology, Qilu Hospital, and.
FAU - Ning, Yun-Na
AU  - Ning YN
FAU - Xu, Miao
AU  - Xu M
FAU - Hou, Yu
AU  - Hou Y
FAU - Wang, Ning
AU  - Wang N
FAU - Hou, Xiao-Yan
AU  - Hou XY
FAU - Yu, Ying-Yi
AU  - Yu YY
FAU - Li, Hui
AU  - Li H
FAU - He, Wei-Dong
AU  - He WD
FAU - Shao, Lin-Lin
AU  - Shao LL
FAU - Zhou, Hai
AU  - Zhou H
FAU - Min, Ya-Nan
AU  - Min YN
FAU - Liu, Xin-Guang
AU  - Liu XG
FAU - Shi, Yan
AU  - Shi Y
FAU - Qin, Ping
AU  - Qin P
FAU - Guo, Cheng-Shan
AU  - Guo CS
FAU - Hou, Ming
AU  - Hou M
FAU - Peng, Jun
AU  - Peng J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130807
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Early Growth Response Transcription Factors)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (KLF10 protein, human)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 4Z8R6ORS6L (Thalidomide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Cell Proliferation/drug effects
MH  - Dendritic Cells/*immunology
MH  - Early Growth Response Transcription Factors/genetics/metabolism
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Immune Tolerance/*drug effects
MH  - Immunosuppressive Agents/*pharmacology
MH  - Kruppel-Like Transcription Factors/genetics/metabolism
MH  - Male
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Middle Aged
MH  - Purpura, Thrombocytopenic, Idiopathic/genetics/*immunology/*metabolism
MH  - RNA Interference
MH  - Thalidomide/*pharmacology
MH  - Young Adult
EDAT- 2013/08/09 06:00
MHDA- 2013/11/16 06:00
CRDT- 2013/08/09 06:00
PHST- 2013/08/09 06:00 [entrez]
PHST- 2013/08/09 06:00 [pubmed]
PHST- 2013/11/16 06:00 [medline]
AID - S0006-4971(20)43146-5 [pii]
AID - 10.1182/blood-2013-03-491555 [doi]
PST - ppublish
SO  - Blood. 2013 Sep 19;122(12):2074-82. doi: 10.1182/blood-2013-03-491555. Epub 2013 
      Aug 7.